Poor oral bacteria may hinder blood pressure benefits, but Exeter study finds beetroot juice’s nitrates restore balance, ...

In a study known as CROWNS-2 published in JAMA, the researchers randomly assigned 180 adults with CRSwNP to stapokibart (300 ...

Celldex has stopped development of barzolvolimab in eosinophilic esophagitis (EoE) despite meeting its primary endpoint in a ...

Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile ...

Viking Therapeutics said Tuesday its experimental weight-loss pill helped patients lose 12.2% of their body weight in a ...

The FDA has approved semaglutide for treating MASH, a significant advancement in liver disease management. Semaglutide, ...

Viking Therapeutics reported a large number of patients dropped out of a study of its experimental weight-loss pill.

Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off ...

One promising option is turmeric, a bright yellow spice commonly used in cooking. Its active compound, curcumin, has shown ...

Viking Therapeutics reports positive top-line results from phase 2 VENTURE-Oral Dosing trial of VK2735 tablet formulation in patients with obesity: San Diego Wednesday, August 20, ...

The participants will receive either 100 mg of verekitug every 12 weeks, 400 mg every 24 weeks, or a placebo, throughout 60 ...

Viking Therapeutics' stock crashed 40% in early trading on Tuesday after a phase 2 trial of its weight-loss pill showed a ...